Nautilus Biotechnology Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong execution on commercialization plans, reduced operating expenses, and expanded early access engagement, with Baylor College of Medicine as the first named EAP customer. Cash runway extends through 2027, and commercial launch remains on track for late 2026.
-
Proteomics remains a critical bottleneck in drug development, with current technologies lacking depth and reproducibility. Nautilus is introducing a disruptive platform with novel assays and a high-throughput instrument, aiming for broad market adoption and significant revenue ramp by mid-next year.
-
A novel proteomics platform was showcased, offering unprecedented sensitivity and reproducibility for both broadscale and targeted protein analysis. Early access programs are underway, with commercial launch and expanded assay portfolio expected by next year.
Fiscal Year 2025
-
Q4 2025 saw major technical and commercial milestones, including the Voyager instrument debut and early access program launch. Operating expenses and cash burn declined year-over-year, with commercial launch and revenue ramp expected in 2027.
-
Q3 2025 saw major scientific advances, expanded collaborations, and disciplined expense management, with operating expenses down 19% year-over-year and a strong cash position. Early access for the Tau assay launches in H1 2026, with broad-scale launch targeted for late 2026.
-
A new proteomics platform aims to revolutionize drug discovery by enabling comprehensive, high-precision protein analysis, addressing inefficiencies in current R&D and unlocking AI-driven biomedical advances. Commercial launch is planned for late 2026, with strong financial backing and leadership alignment.
-
A new proteomics platform is set to launch at the end of next year, aiming for comprehensive proteome analysis and high reproducibility, with initial applications in neurodegenerative disease. The company is prioritizing broad-scale discovery, maintaining strong financial discipline, and preparing for a $1 million bundled offering.
-
Q2 2025 saw a milestone with public validation of a unique proteoform platform, strong cross-sector interest, and two major research collaborations. Operating expenses and net loss declined year-over-year, with a robust cash position and a clear roadmap for product and revenue ramp in 2026–2027.
-
A novel proteomics platform aims to deliver comprehensive protein analysis, addressing current limitations in mass spectrometry and enabling new discoveries in drug development and disease research. Commercial launch is planned for late 2026, with early access programs and targeted assays in 2025.
-
Q1 2025 saw major progress in tau proteoform assay validation, strong customer interest, and ongoing partnership discussions. Operating expenses and net loss declined year-over-year, with a cash runway projected through 2027 and platform launch on track for late 2026.
-
A novel proteomics platform aims to deliver near-complete protein analysis with single-molecule sensitivity, targeting pharma, diagnostics, and research markets. Commercial launch is delayed to late 2026 due to technical challenges, but early proteoform assays are progressing with pharma partnerships and minimal near-term revenue.
Fiscal Year 2024
-
Platform launch delayed to late 2026 to optimize performance, with early access for tau proteoform studies in 2025. FY 2024 net loss increased 11% to $70.8M, and a 16% workforce reduction extends cash runway through 2027.
-
A novel proteomics platform is set to launch in late 2025, offering unprecedented sensitivity and scale for protein analysis, with early access programs targeting key opinion leaders and pharma partners. Financial discipline has preserved significant cash runway, and leadership experience supports ambitious growth plans.
-
Q3 2024 saw strong progress in proteoform detection and platform integration, though broad-scale milestones lagged. Operating expenses remained flat, cash runway extends into 2027, and commercial launch is still targeted for late 2025, with early proteoform collaborations planned.
-
The platform aims to revolutionize proteomics by enabling comprehensive, high-sensitivity protein analysis using PrISM technology, with a user-friendly workflow and cloud-based data management. Launch is targeted for 2025, supported by strong financial discipline and ongoing collaborations.
-
Q2 2024 saw continued platform development, improved financial discipline, and strong research community engagement. Commercial launch remains on track for 2025, with cash runway into the second half of 2026 and reduced OpEx guidance supporting long-term execution.
-
A 2025 launch is planned for a proteomics platform offering single-molecule sensitivity and broad protein coverage, targeting a $5–10 billion initial market. Customer excitement centers on deep, accessible protein analysis and proteoform insights, with strong financial discipline and a focused sales approach supporting the rollout.